NextFin news, groundbreaking research emerging from a multi-institutional Phase II clinical trial known as SOLACE2, conducted across 15 Australian hospitals, has identified a novel blood test that can predict ovarian cancer patients’ responsiveness to PARP inhibitor therapy. The trial, co-led by the University of Sydney NHMRC Clinical Trials Centre, RMIT University, and the Walter and Eliza Hall Institute (WEHI), and coordinated by the Australia New Zealand Gynaecological Oncology Group (ANZGOG), announced these findings in the journal Nature Communications in November 2025.
This new companion diagnostic test measures immune biomarkers indicating the mobilization of cytotoxic immune cells towards tumor sites and tracks inflammatory processes associated with cancer progression and resistance. This approach diverges from the existing HRD (homologous recombination deficiency) genomic test that screens tumor DNA for defects in DNA repair mechanisms—currently the gold standard for selecting candidates for PARP inhibitors.
Over 300,000 women globally are diagnosed with ovarian cancer annually, with 1,700 new cases recorded in Australia alone each year. PARP inhibitor therapy, which blocks the PARP enzyme essential for cancer cells’ DNA repair, is typically prescribed for HRD-positive patients. However, clinical observations have revealed inconsistencies: some HRD-negative patients respond well, while certain HRD-positive cases do not benefit, underscoring the need for a more sensitive and dynamic predictive test.
The SOLACE2 trial also tested immune system priming strategies—combining cyclophosphamide and immunotherapy with PARP inhibitors—to boost treatment efficacy. It was amid these trials that researchers discovered the power of real-time immune response profiles in blood to better predict patient outcomes.
According to Distinguished Professor Magdalena Plebanski of RMIT, the blood test assesses a real-time immune signature rather than static tumor DNA repair status, enabling more accurate identification of patients who will profit from PARP inhibitors. This test, which is pending further validation and regulatory approval, could dramatically streamline patient stratification, avoiding ineffective treatments and their associated costs and toxicities.
Professor Clare Scott of WEHI highlighted the critical finding that the migration of effector T cells into tumors is a key determinant of treatment response. Enhancing this immune cell infiltration may be a future therapeutic axis to augment PARP inhibitor efficacy.
The SOLACE2 results showed that a three-month immune priming phase delayed ovarian cancer recurrence post-therapy, indicating beneficial synergy between immune modulation and DNA repair inhibition. While these clinical findings require confirmation in larger trials, they open the door for integrating immune biomarker tests into clinical decision-making frameworks.
From an industry perspective, this development could significantly impact oncology drug markets and diagnostics. The ability to accurately select patients for costly PARP inhibitors—whose treatment costs can range from $70,000 to $120,000 annually in the U.S.—promises to optimize healthcare resource utilization and improve patient quality of life by minimizing unnecessary exposure to ineffective therapies.
The test’s reliance on peripheral blood samples rather than tumor biopsies addresses current practical limitations, such as tumor tissue availability and temporal changes in tumor genomics, thus enhancing test accessibility and repeatability for ongoing monitoring.
Strategically, the test illustrates the growing paradigm shift toward immunogenomic profiling in oncology, where dynamic host immune interactions are integrated with tumor genomic data to refine personalized medicine. This approach aligns with broader trends in cancer treatment emphasizing immunotherapy combinations and biomarker-driven therapy adjustments.
Looking forward, successful validation and commercial deployment of this blood test will likely stimulate further research into immune mechanisms underlying PARP inhibitor sensitivity and resistance. It may also encourage pharmaceutical and biotech companies to develop complementary agents that increase immune cell trafficking into tumors, thereby enhancing the efficacy of existing PARP inhibitors.
Moreover, healthcare policy and reimbursement models will need to adapt by prioritizing diagnostics that enable precision oncology, which is aligned with ongoing initiatives by the U.S. Food and Drug Administration and European Medicines Agency to fast-track companion diagnostics paired with targeted therapies.
Overall, this blood test breakthrough, as reported by Medical Xpress citing RMIT University’s research, represents a significant leap toward truly personalized ovarian cancer care, promising to reduce mortality and improve response rates by matching the right patients with the most effective PARP inhibitor regimens.
Explore more exclusive insights at nextfin.ai.
